DiaSorin S.p.A. (OTCMKTS:DSRLF) Receives Consensus Recommendation of “Hold” from Analysts

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) have received a consensus rating of “Hold” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company.

DSRLF has been the subject of a number of research analyst reports. Zacks Research upgraded DiaSorin to a “hold” rating in a report on Tuesday, May 12th. Deutsche Bank Aktiengesellschaft cut shares of DiaSorin from a “hold” rating to a “sell” rating in a research report on Wednesday, June 17th. Piper Sandler assumed coverage on shares of DiaSorin in a research note on Thursday, June 11th. They issued a “neutral” rating for the company. BNP Paribas Exane lowered shares of DiaSorin from a “neutral” rating to an “underperform” rating in a research note on Tuesday. Finally, UBS Group cut shares of DiaSorin from a “buy” rating to a “neutral” rating in a report on Thursday, April 9th.

DiaSorin Stock Performance

DSRLF stock opened at $81.00 on Friday. DiaSorin has a 12-month low of $66.50 and a 12-month high of $100.00. The business’s fifty day moving average price is $74.70 and its 200 day moving average price is $76.22.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.